Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH: Switching to QVA149 in COPD
NCT02516592Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 4 trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Oct 2015; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02516592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516592.